BlackRock, Inc.’s Heaviest Healthcare Share Positions: JNJ, VRX, PFE

Wall St. Watchdog reveals information regarding BlackRock, Inc.’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 348 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $2.291 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, BlackRock, Inc. reported holding 4,156,919 shares with a market value of $276,518,238. This comprised 0.54% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 4,326,534 shares with a market value of $275,556,945. This comprised 0.62% of the total portfolio. The net change in shares for this position over the two quarters is 169,615. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Valeant Pharmaceuticals International (NYSE:VRX): On 06/30/2011, BlackRock, Inc. reported holding 6,740,744 shares with a market value of $350,249,052. This comprised 0.69% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 6,688,585 shares with a market value of $248,280,268. This comprised 0.56% of the total portfolio. The net change in shares for this position over the two quarters is -52,159. About Company: Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders; and distributes generic and branded generic drugs in Latin America and Eastern Europe.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, BlackRock, Inc. reported holding 13,683,613 shares with a market value of $281,882,433. This comprised 0.55% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 13,850,836 shares with a market value of $244,882,785. This comprised 0.56% of the total portfolio. The net change in shares for this position over the two quarters is 167,223. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, BlackRock, Inc. reported holding 5,055,716 shares with a market value of $178,416,222. This comprised 0.35% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 4,280,428 shares with a market value of $139,969,999. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is -775,288. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, BlackRock, Inc. reported holding 1,988,995 shares with a market value of $104,660,915. This comprised 0.21% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 1,639,729 shares with a market value of $83,855,740. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is -349,266. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, BlackRock, Inc. reported holding 3,972,301 shares with a market value of $115,037,833. This comprised 0.23% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 2,536,361 shares with a market value of $79,591,006. This comprised 0.18% of the total portfolio. The net change in shares for this position over the two quarters is -1,435,940. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, BlackRock, Inc. reported holding 1,714,838 shares with a market value of $100,060,795. This comprised 0.2% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 1,438,351 shares with a market value of $79,051,770. This comprised 0.18% of the total portfolio. The net change in shares for this position over the two quarters is -276,487. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Biogen Idec Inc. (NASDAQ:BIIB): On 06/30/2011, BlackRock, Inc. reported holding 663,851 shares with a market value of $70,978,948. This comprised 0.14% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 811,620 shares with a market value of $75,602,404. This comprised 0.17% of the total portfolio. The net change in shares for this position over the two quarters is 147,769. About Company: Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, BlackRock, Inc. reported holding 1,705,669 shares with a market value of $87,978,410. This comprised 0.17% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 1,584,133 shares with a market value of $73,060,212. This comprised 0.17% of the total portfolio. The net change in shares for this position over the two quarters is -121,536. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Allergan Inc. (NYSE:AGN): On 06/30/2011, BlackRock, Inc. reported holding 873,481 shares with a market value of $72,717,293. This comprised 0.14% of the total portfolio. On 09/30/2011, BlackRock, Inc. reported holding 879,311 shares with a market value of $72,437,638. This comprised 0.16% of the total portfolio. The net change in shares for this position over the two quarters is 5,830. About Company: Allergan, Inc. is a multi-specialty health care company that discovers, develops and commercializes pharmaceuticals, biologics and medical devices. The Company develops products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in countries around the world.

(Note: Data regarding BlackRock, Inc.’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>